New SLE and SPE Automation System from Biotage
Biotage has launched of the new Biotage Extrahera, an automated system for the processing of supported liquid extraction (SLE) and solid phase extraction (SPE) methods in both plate and column formats — making the system a flexible option for a wide variety of analytical laboratories.
Biotage Extrahera is a compact eight channel automation system that can handle 96 & 48 fixed well plate formats and 1 mL, 3 mL or 6 mL columns. The instrument has been designed for speed and flexibility and is capable of processing a complete 96-well plate SPE method in less than 30 minutes. The system comes pre-loaded with Biotage SPE and SLE methods for plates and columns, while new methods can be created in minutes; using the feature rich software, operators are able to just press “Start” and walk away.
By automating SPE or SLE methods the Biotage Extrahera removes workflow bottlenecks in the laboratory; the higher throughput lowers the cost per sample of analysis and enables skilled analysts to be redeployed to other, more demanding tasks, such as data analysis. Automation also ensures that samples are prepared identically every time, regardless of the sample matrix, improving accuracy and precision of results.
“Sample preparation can be a laborious, time consuming process — implementing Biotage Extrahera ensures that samples can be being generated to feed an MS system as fast as the extraction method permits and as fast as an end user can provide suitable samples for extraction” says Paul Roberts, Analytical Product Manager, Biotage.
Biotage Extrahera utilises a minimum of moving parts with easily accessible consumables and has been designed to minimize any potential cross contamination. Using positive pressure during processing provides more control and uniformity of flows across multiple columns and wells. The enclosed working area also ensures operator safety and reduces their exposure to solvents and hazardous compounds.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.